These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32873693)

  • 1. Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.
    Luo J; Agboola F; Grant E; Masters CL; Albert MS; Johnson SC; McDade EM; Vöglein J; Fagan AM; Benzinger T; Massoumzadeh P; Hassenstab J; Bateman RJ; Morris JC; Perrin RJ; Chhatwal J; Jucker M; Ghetti B; Cruchaga C; Graff-Radford NR; Schofield PR; Mori H; Xiong C
    Neurology; 2020 Dec; 95(23):e3104-e3116. PubMed ID: 32873693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.
    Luo J; Agboola F; Grant E; Morris JC; Masters CL; Albert MS; Johnson SC; McDade EM; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Wang G; Li Y; Gordon B; Cruchaga C; Day GS; Levin J; Vöglein J; Ikeuchi T; Suzuki K; Allegri RF; Xiong C;
    Brain; 2022 Dec; 145(12):4459-4473. PubMed ID: 35925685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
    Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
    Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer disease biomarkers are associated with body mass index.
    Vidoni ED; Townley RA; Honea RA; Burns JM;
    Neurology; 2011 Nov; 77(21):1913-20. PubMed ID: 22105948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.
    Xiong C; Jasielec MS; Weng H; Fagan AM; Benzinger TL; Head D; Hassenstab J; Grant E; Sutphen CL; Buckles V; Moulder KL; Morris JC
    Neurology; 2016 Apr; 86(16):1499-506. PubMed ID: 27009258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
    JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.
    Apostolova LG; Hwang KS; Andrawis JP; Green AE; Babakchanian S; Morra JH; Cummings JL; Toga AW; Trojanowski JQ; Shaw LM; Jack CR; Petersen RC; Aisen PS; Jagust WJ; Koeppe RA; Mathis CA; Weiner MW; Thompson PM;
    Neurobiol Aging; 2010 Aug; 31(8):1284-303. PubMed ID: 20538372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.